MARKET

APOP

APOP

Cellect Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.030
-0.050
-1.62%
Closed 17:31 01/26 EST
OPEN
3.040
PREV CLOSE
3.080
HIGH
3.180
LOW
3.020
VOLUME
102.03K
TURNOVER
--
52 WEEK HIGH
5.40
52 WEEK LOW
0.4000
MARKET CAP
11.85M
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
Promising Progress on Clinical Development Progress, Collaborations and Partnering
GlobeNewswire · 11/20/2020 13:33
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
Promising Progress on Clinical Development Progress, Collaborations and Partnering
GlobeNewswire · 11/20/2020 13:33
Cellect Biotechnology Q3 EPS $(0.01) Up From $(0.12) YoY
Cellect Biotechnology (NASDAQ:APOP) reported quarterly losses of $(0.01) per share. This is a 91.67 percent increase over losses of $(0.12) per share from the same period last year.
Benzinga · 11/20/2020 13:07
Cellect Biotechnology reports Q3 results
Cellect Biotechnology (APOP): Q3 GAAP EPS of $0.00.Cash and cash equivalents of $6.07M.Press Release
Seekingalpha · 11/20/2020 13:03
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
Promising Progress on Clinical Development Progress, Collaborations and Partnering Mutually Ended Discussion on Medical Cannabis Commercial and Merger AgreementsTEL AVIV, Israel, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP),...
GlobeNewswire · 11/20/2020 13:00
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
Promising Progress on Clinical Development Progress, Collaborations and Partnering Mutually Ended Discussion on Medical Cannabis Commercial and Merger AgreementsTEL AVIV, Israel, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2020. Subsequent to the end of the third quarter, the Company announced several other key achievements subsequent to the end of the third quarter that position it for continued success in 2021, including clinical and operational objectives: * Initiated its clinical trial in the U.S. The trial is being performed at Washington University School of Medicine in St. Louis, Missouri, which is among the leading medical centers in the U.S. The Principal Investigator for the clinical trial is Zhifu Xiang, M.D., of Washington University. He is an Associate Professor in the Division of Oncology's Bone Marrow Transplantation & Leukemia Section in the Department of Medicine. John Dipersio M.D, Ph.D., will act as co-Principal Investigator for the study. He is the chief of the Division of Oncology in the Department of Medicine at Washington University. * Entered into a collaborative agreement with the Swedish XNK Therapeutics, enabling it to leverage Cellect’s technology in Natural Killer cell therapies. XNK is a clinical stage Swedish company working with the Karolinska Institute.“In spite of the COVID-19 challenges we expedited our clinical and business development activities as we successfully achieved several objectives,” commented Dr. Shai Yarkoni, Chief Executive Officer. “Specifically, we recently initiated our U.S. clinical trial and entered into a partnership with a clinical stage biotech company that will leverage our functional cell selection technology. I believe these results reflect our steadfast determination and success progressing our clinical trials, which also includes the trial in Israel, combined with the latest collaboration agreement with XNK Therapeutics gives us multiple shots on goal to maximize shareholder value. We believe, based on our internal evaluation and assessment, that each of these opportunities could potentially represent significant revenue streams in the coming years.”Separately, Cellect and Canndoc Ltd. have mutually agreed to end previously announced commercial and merger discussions. The Company will continue to pursue a partner that can bring value to its shareholders and progress the development of the Company’s platform technology.The Company's cash and cash equivalents totaled $6.07 million as of September 30, 2020. The Company will use its resources to progress clinical and business development efforts to advance its functional cell selection technology. The Company has sufficient funds to operate in the next 15 months. Reference is made to Note 1. C (Going Concern) in the Interim Consolidated Financial Statements as of June 30th, 2020, which were filed as an exhibit to a Form 6-K dated August 12, 2020.Third Quarter 2020 Financial Results: * Research and development (R&D) expenses for the third quarter of 2020 were $0.37 million, compared to $0.72 million in the third quarter of 2019. The decrease in the R&D expenses is primarily due to decrease in clinical activities as a result of the COVID-19. * General and administrative (G&A) expenses for the third quarter of 2020 were $0.36 million compared to $0.80 million in the third quarter of 2019. The decrease in G&A expenses was primarily due to the decrease in professional expenses. * Finance income for the third quarter of 2020 were $0.26 million, compared to finance income of $0.12 million in the third quarter of 2019. The change was primarily due to changes related to the fair value of the tradable and non-tradable warrants issued in a prior fundraising. * Net loss for the third quarter of 2020 was $0.47 million, or $0.001 per share compared to $1.40 million, or $0.006 per share in the third quarter of 2019.* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on September 30, 2020 (U.S. $1 = NIS 3.441).About Cellect Biotechnology Ltd.Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of cell based therapies.The Company's technology is expected to provide researchers, clinical community, and pharma companies with the tools to rapidly isolate specific cells in quantity and quality allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.Forward Looking Statements         This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company’s ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC.Contact Cellect Biotechnology Ltd. Eyal Leibovitz, Chief Financial Officer www.cellect.co  +972-9-974-1444OrEVC Group LLC Michael Polyviou (732) 933-2754 mpolyviou@evcgroup.com Cellect Biotechnology Ltd Consolidated Statement of Operation  Convenience           translation           Nine months ended Nine months ended Three months ended   September 30, September 30, September 30,   2020 2020 2019 2020 2019         Unaudited Unaudited   U.S. dollars NIS       (In thousands, except share and per share data)             Research and development expenses 1,218 4,190 9,551 1,289 2,465             General and administrative expenses 1,727 5,944 7,832 1,241 2,768             Operating loss 2,945 10,134 17,383 2,530 5,233             Financial expenses (income) due to warrants exercisable into shares 790 2,717 (8,020) (1,090) (910)             Other financial expenses, net 40 138 1,369 193 489             Total comprehensive loss 3,775   12,989 10,732 1,633 4,812             Loss per share:                       Basic and diluted loss per share 0.010 0.036 0.051 0.004 0.021             Weighted average number of shares outstanding used to compute basic and diluted loss per share 390,949,079 390,949,079 208,771,303 390,949,079 224,087,799 Cellect Biotechnology Ltd. Consolidated Balance Sheet Data Convenience       translation       September 30, September 30, December 31,   2020  2020  2019  Unaudited Unaudited Audited  U.S. dollars NIS  (In thousands, except share and per share data) CURRENT ASSETS:      Cash and cash equivalents6,071  20,889  18,106  Other receivables205  707  469   6,276  21,596  18,575  NON-CURRENT ASSETS:      Restricted cash96  329  328  Right-of-use assets238  819  1,035  Other long-term receivables19  66  94  Property, plant and equipment, net379  1,304  1,288   732  2,518  2,745          7,008  24,114  21,320    CURRENT LIABILITIES:      Trade payables71  243  158  Other payables579  1,994  3,080  Current maturities of lease liability136  468  396   786  2,705  3,634  NON-CURRENT LIABILITIES:      Warrants to ADS354  1,218  2,172  Lease liability112  386  677   466  1,604  2,849  EQUITY:      Ordinary shares of no par value:       Authorized: 500,000,000 shares at December 31, 2019 and September 30, 2020; Issued and outstanding: 390,949,079*) and 224,087,799*) shares as of December 31, 2019 and September 30, 2020, respectively.-  -  -  Additional Paid in Capital36,861  126,839  108,598  Share-based payments4,721  16,244  16,528  Treasury shares(2,739) (9,425) (9,425) Accumulated deficit(33,087) (113,853) (100,864)  5,756  19,805  14,837          7,008  24,114  21,320  *)    Net of 2,641,693 treasury shares of the Company held by the Company. Cellect Biotechnology Ltd Consolidated Cash Flow Data Convenience          translation          Nine months endedNine months ended Three months ended  September 30,September 30, September 30,  2020 2020  2019  2020  2019      UnauditedUnaudited  U.S. dollarsNIS  (In thousands) Cash flows from operating activities:         Total comprehensive loss(3,775)(12,989) (10,732) (1,633) (4,812)           Adjustments to reconcile net loss to net cash used in operating activities:         Exchange rate difference(61)(211) -  (216) -  Net financing expenses14 48  1,087  11  272  Loss (gain) from revaluation of financial assets presented at fair value through profit and loss- -  8  -  2  Depreciation75 256  285  86  93  Changes in fair value of traded and not traded warrants790 2,718  (9,351) (1,089) (910) Share-based payment138 476  1,901  (353) 1,371  Decrease (increase) in other receivables(61)(210) 146  263  -  Decrease in other payables(334)(1,149) (1,855) (396) (1,138) Depreciation of Right of use - Assets under operating lease79 272  457  89  143  Interest received during the period16 56  (75) 21  (29) Net cash used in operating activities(3,119)(10,733) (18,129) (3,217) (5,008)           Cash flows from investing activities:         Restricted deposit, net- (1) -  1  -  Sales (Purchase) of property, plant, and equipment(36)(124) (120) (155) -  Net cash provided by investing activities(36)(125) (120) (154) -            Cash flows from financing activities:         Exercise of warrants and stock options into shares1,341 4,615  -  (92) -  Leases liabilities(94)(324) (422) (112) (143) Issue of share capital and warrants, net of issue costs2,672 9,194  23,723  -  -  Net cash provided (used) by financing activities3,919 13,485  23,301  (204) (143) Exchange differences on balances of cash and cash equivalents45 156  (1,012) 195  (243) Increase (decrease) in cash and cash equivalents809 2,783  4,040  (3,380) (5,394) Balance of cash and cash equivalents at the beginning of the period5,262 18,106  17,809  24,269  27,243  Balance of cash and cash equivalents at the end of the period6,071 20,889  21,849  20,889  21,849
GlobeNewswire · 11/20/2020 13:00
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology
Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a collaborative development program with Sweden-based XNK Therapeutics, a pioneer in natural killer (NK) cell-based therap...
GlobeNewswire · 10/29/2020 16:55
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology
Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a collaborative development program with Sweden-based XNK Therapeutics, a pioneer in natural killer (NK) cell-based therap...
GlobeNewswire · 10/29/2020 12:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Balance SheetMore
Cash FlowMore
OperatingInvestingFinancing
Learn about the latest financial forecast of APOP. Analyze the recent business situations of Cellect Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APOP stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 747.05K
% Owned: 19.11%
Shares Outstanding: 3.91M
TypeInstitutionsShares
Increased
1
2.28K
New
5
66.49K
Decreased
2
54.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Director
Nuriel Kasbian
Chief Executive Officer/Director
Shai Yarkoni
Chief Financial Officer
Eyal Leibovitz
Vice President - Research & Development
Amotz Nehushtan
Other
Yaron Pereg
Other
Guy Sapir
Director
Ruth Ben Yakar
Director
Michael Berelowitz
Non-Executive Director
Yuval Berman
Non-Executive Director
David Grossman
Independent Director
Abraham Nahmias
  • Dividends
  • Splits
  • Insider Activity
No Data
About APOP
Cellect Biotechnology Ltd is an Israel-based biotechnology company. Its technology platform, ApoGraft, selects stem cells to improve the safety and efficacy of regenerative medicine and cell therapies by using functional selection. Efficient selection enables retention of most of the stem cells while neutralizing harmful mature cells. ApoGraft exploit a functional characteristic of stem cells relating to apoptosis, which is the process of programmed cell death and is a vital part of physiological development and homeostasis of all organisms. Stem cells flourish in an environment where normal cells die because their main role is reconstitution of damaged tissue. The platform is being tested for clinical use in allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematological malignancies. Additionally, the Company is developing its first product based on its platform, the ApoTainer selection kit that utilizes FasL-coated paramagnetic beads.

Webull offers kinds of Cellect Biotechnology Ltd - ADR stock information, including NASDAQ:APOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APOP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APOP stock methods without spending real money on the virtual paper trading platform.